Therefore, the anti‐tumor activity of zosuquidar is extremely relies on the expression of PD‐L1 and the presence of immune system, which were not considered in previous clinical trials.[40] Thus, the clinical benefits of zosuquidar might deserve further evaluation, and we provided a theoretical basis for its application in NSCLC therapy from an immune perspective. Here, CD274 is linked to non-small cell lung carcinoma.